In this short review, we put emphasis on the importance of ETS transcription factor family, and more especially of its founder Ets-1, in the control of epithelium-mesenchyme dialogues. In the context of tumor progression, Ets-1 expression can be induced by various stromal instructive signals. Reciprocally, integration of these various microenvironmental influences via Ets-1 will result in the remodeling of the extracellular matrix by tumor cells. We sum up the current knowledge about the balance between cell growth and invasion orchestrated by EMT drivers, among which Ets-1, and the growing evidence that EMT needs to be spatio-temporally regulated along tumor progression and metastasis. We eventually discuss the impact these data have on our understanding of tumorigenesis, and the consideration they should be given when elaborating therapeutic anticancer strategies.
Introduction
Over the last years, cancer research has clearly established that beyond the complexity of molecular disorders driving most tumors lies a complex network of interactions between tumors and their microenvironment. From that point of view, cancer cells benefit from a conspiracy orchestrated by the tumor microenvironment. Elucidating the signals triggering this malignant response, and which signalling pathways mediate this sinister contribution should open new therapeutic windows.
The microenvironment can influence tumor progression in different manners. First of all, stromal cells such as cancer-associated fibroblasts or immune cells secrete many growth factors and cytokines which can foster tumor growth (for review, see [1, 2] ). The surrounding extracellular matrix can also regulate the tumoral behaviour by the induction of instructive signals encoded by its composition, the modulation of adhesive and migratory characteristics, and by the mechano-transduction induced via its stiffness.
The tumor microenvironment invasion model (TMIM) proposed by Condeelis et al, states that invasion elicited by tumor cells is somehow comparable with embryonic morphogenetic programs [3] . The various signals transmitted by the tumor stroma will be received and integrated by the tumor cells via different signalling pathways. Transcription factors play a key role as integrators of such signals allowing the expression of hijacked genetic programs.
REVIEW
ETS family transcription factors can regulate many biological processes and Ets-1, the founder of this family, has been especially associated with epithelium-mesenchyme interactions.
During embryogenesis, the c-ets-1 proto-oncogene is notably expressed by neural crest cells undergoing epithelial-to-mesenchymal transition (EMT) [4] and by terminal end buds within the mammary gland [5] . ETS family factors, and especially Ets-1, are also overexpressed in various cancers and can modulate cancer cell behaviour in the tumor microenvironment. In this review we gather the most recent information about Ets-1 function in the reciprocal interactions exerted between tumors and their microenvironment.
ETS factor family expression in human cancers

ETS fusion proteins in cancers
The importance of ETS transcription factors in cancers is highlighted by the existence of fusion genes encoding aberrantly regulated ETS factors and driving malignancy. For instance, a chromosomal translocation driving the expression of a EWS-FLI1 chimera is found in the vast majority of Ewing sarcomas. Fusions of the EWS gene with other ETS family factors such as ERG or ETV1 have also been reported in other subsets of Ewing sarcomas (for review, see [6] ). More recently, fusion of ETS factors with the androgen-regulated TMPRSS2 gene has been identified in most prostate cancers, with a predominance of TMPRSS2-ERG fusions [7, 8] .
ETS abnormal expression in human cancers
The expression of ETS factors is also increased in various carcinomas as a result of the overexpression of the wild-type protein. Since its discovery in the early 80s as an orthologue of the avian oncogene ETS (E Twenty-six Specific) [9] , the proto-oncogene c-ets-1 was shown to be involved in the progression of several human cancers, and has been especially associated with invasive characteristics of carcinomas. In breast cancers for example, the Matrix-MetalloProteinases (MMPs) maturation and secretion was enhanced , allowing the degradation or remodeling of physiologically relevant reconstituted extracellular matrix (ECM) of collagen+Matrigel® mixture, in association with increased migratory or invasive potentials in 2D plastic assays, transwell® migration or invasion assays, and in morphogenesis assays in 3D ECM-mimicking gels. In addition, Ets-1 overexpression decreased the density of breast cancer cells cultured in such matrix-mimicking gels. The 3D context was instrumental to this phenomenon. Ets-1 overexpression was also deleterious to proliferation recorded in 3D in vitro assays anchorage-independent assays and for growth of MMT cells in soft agar, a standard model for in vitro tumorigenicity. The relevance of this mechanism was confirmed in vivo, during primary tumor growth in the flank and in a metastatic assay of lung colonization after intravenous injections in the tail vein. These in vitro and in vivo observations showed that while promoting malignancy through the acquisition of invasive features, Ets-1 also can attenuate breast tumor cell growth and could therefore repress the growth of primary tumors and metastases.
overexpression of Ets-1 or that of the ETV subfamily factors have thus been reported [10, 11] . In invasive breast carcinomas, Ets-1 overexpression was first reported in the stroma at the tumor margin interface then in tumor cells [12 13] . In such cancers, Ets-1 expression is associated with Scarff-Bloom-Richardson grading and poor prognosis [13, 14] . In the last years, Ets-1 overexpression has also been associated with a poor clinical outcome in prostate and colorectal cancers [15, 16] among others. Inversely, some ETS transcription factors rather play a tumor suppressor role and see their expression down-regulated in cancers, such as Pdef, Fli1 and ESE-3 [17] [18] [19] .
Ets-1 and the interactions between tumors and their microenvironment
As evidenced by their aberrant expression in both tumors and their microenvironments, ETS transcription factors influence the complex crosstalk established between cancer cells, stromal cells and their surrounding extracellular matrix.
Control of extracellular matrix composition by ETS factors
Many ETS target genes have been described so far, regulating a wide panel of biological responses (for review, see [20] ), with a recent emphasis on the control by Ets-1 of energy metabolism in cancer cells [21] .
In cancers, Ets-1 overexpression has been particularly associated with the control of cell migration and invasion in the surrounding Extra-Cellular Matrix (ECM), and the up-regulation of matrix-degrading proteases such as urokinase-type Plasminogen Activator (uPA) [5] or Matrix MetalloProteinases (MMPs) [12] . We have shown that Ets-1 transcription factor notably orchestrated the invasive phenotype of mammary cancer cells in ECM via the coordination of integrins and MMPs' expression and activity [22] ( figure 1, right part) . We also obtained unpublished data evidencing a control by Ets-1 of fibrillar ECM production and remodelling by these cells, with Ets-1 overexpression impairing the deposit/organization of ECM fibers and promoting their degradation. It is also noteworthy that ETS factors' expression in the stroma also controls the composition of the tumor-surrounding matrix. It has thus been shown that Pten loss in the stromal fibroblasts contributed to mammary tumor growth in association with a massive ECM remodelling requiring Ets-2 [23] . Finally, Fli1 is another important regulator of ECM composition, notably via the control of collagen fibrillogenesis [24] .
Ets-1 in the epithelium-mesenchyme dialogue
The expression pattern of several ETS transcription factors during embryogenesis is highly associated with tissues undergoing morphogenesis (for review, see [25] ). Ets-1 is thus expressed in mesodermal cells located near epithelial structures undergoing inductive epithelium-mesenchyme processes [26] . Epithelial-mesenchymal interactions trigger Ets-1 and uPA expression in both compartments of the mammary gland undergoing morphogenesis [5] . Ets-1 expression is also highly associated with invasive features during tumorigenesis. During breast cancer progression, Ets-1 and its metalloproteinase target genes are up-regulated both in epithelial and stromal cells in association with cancer invasiveness [12] . In these cancers, Ets-1 overexpression is not dependent on chromosomal rearrangements but rather induced by different conditions exacerbated in the tumor microenvironment such as hypoxia [27] (figure1, bottom part). Several growth factors or cytokines frequently present in the stroma can also trigger Ets-1 expression [28] , and Ets-1 was recently shown to be required as an effector of RAS/ERK signaling for the migration of epithelial cells from several tissues [29] . Other ETS factors were also described to be overexpressed in cancers and associated with their invasiveness. For example, an overexpression of Erg and ETV1 was observed in prostate cancers originating from the peripheral zone, where usually more invasive and aggressive cancers develop [30] . On the opposite, some ETS transcription factors playing tumor suppressive roles are associated with a repression of invasive features. Pdef has thus been shown to dampen EMT via both Slug-dependent and -independent mechanisms in breast cancer cells [31] , and ESE3/EHF represses the expression of key EMT genes such as twist1 and zeb2 in prostate cancer cells [32] .
The hidden side of Ets-1; when migration interferes with proliferation
We have recently evidenced that the exacerbated invasion promoted by Ets-1 overexpression was counterbalanced by a decrease in cell growth in three-dimensional models in vitro and in vivo [33] (Figure 1 , left part).
Previously, it had been shown in untransformed epithelial cells that the overexpression of another ETS factor, namely ESX/ESE1, could trigger an EMT and a concomitant decrease in cell proliferation [34] . This fits with the concept that migration and proliferation require distinct cytoskeletal rearrangements and can't occur simultaneously. Transcriptomic analyses of invasive cancer cells actually highlighted a population "neither dividing nor apoptotic but intensely motile" [35] . It has then been shown in vivo that melanoma cells switch between proliferative and invasive states [36] . More recently, studies based on conditional transgenic mice smartly demonstrated that whereas the EMT inducer Twist1 promoted the dissemination of squamous cell carcinoma cells, its extinction was then required to allow the growth of metastases from these cells [37] .
The negative impact of EMT drivers on tumor cell growth may account for the specific space distribution of proliferative and invasive activities observed for example in colorectal cancer [38] . The profiling of human breast tumors with hyaluronan probes also revealed a great cellular heterogeneity, with the identification of an invasive but slow-growing breast tumor subset [39] . Interestingly, Ets-1 has been recently shown to be required for CD44 (the hyaluronan receptor) expression and chemotaxis in lung cancer cells [40] .
It is noteworthy that this cellular balance between cell growth and invasion probably has clinical consequences since anti-proliferative therapies may spare cells undergoing invasive processes. Moreover we can envision identifying peculiar molecular signatures predictive of increased susceptibility to develop metastasis.
Ets-1 like other EMT drivers favors epithelial cell dissociation and invasion [22] and probably contributes in this way to the cell dissemination during the early metastatic steps. We recently obtained experimental data evidencing the control by Ets-1 of angiogenic potential and of cancer cell interactions with endothelial cells, which are additional mechanisms important for early steps of metastasis (manuscript in preparation).
As illustrated by our studies and others, EMT-associated phenotype can be deleterious for cancer cell growth, and a reverse Mesenchymal-to-Epithelial Transition (MET) may be required for a proper metastatic growth. In this context, a model for metastasis has emerged over the last years with sequential EMT and MET occurring, which reconciles the importance of EMT for the carcinoma cell dissemination from the primary tumors with the observation that metastases often display an epithelial phenotype [41] . From that point of view, one can envision tumor progression as a horizontal division of labor between oncogenes, with some sustaining cell growth while others are devoted to improve cell motility, with a spatio-temporal regulation of molecular events. Ets-1 overexpression would be a transient signal leading to the dissemination of some breast cancer cells, triggered by instructive signals present in the tumor microenvironment but absent, at least partially, once the metastatic cells reach a healthy niche.
Conclusions and perspectives
Ets-1 is an oncogene tightly depending on the microenvironment for its expression and reciprocally modifies it, notably through the remodelling and/or digestion of the ECM. Over the last years, the impact of ECM composition and organization on tumor progression and metastasis has been described (for review, see [42] ), which possibly accounts for the correlation between Ets-1 expression and bad prognosis in various cancers.
Although Ets-1 overexpression has been reported in several carcinomas, the precise topology of such an overexpression is still ill-defined and may help us to better understand the biology of these cancers. For example Ets-1 expression is associated with a poor prognosis in colorectal carcinomas [16] and it could prove valuable to analyze if Ets-1 expression pattern fits with the balance between proliferation and invasion observed in such cancers [38] . The comparison of Ets-1 expression in established metastases vs primary tumors also appears as a key issue to further elucidate the role of Ets-1 during tumor progression. Moreover, considering the microenvironmental influences regulating Ets-1 expression in association with EMT vs MET metastatic phenotypes should be of interest.
Finally, EMT induction has been associated with stem or progenitor features in cancer cells [43, 44] . This may partially underlie the plasticity and heterogeneity observed in tumors, and result in invasive cancer cells with stem cell-like features (for review, see [45] ). Recently, Ohnishi et al have demonstrated that hypoxia was inducing the expression of CD133, which is considered as an indicator of cancer stem cells, thanks to ETS transcription factors [46] . Further studies should unveil whether Ets-1 and other members of the ETS family modulate stem cell traits in cancer cells, which may add another lethal weapon to Ets-1-driven cancer cell oncogenic battery.
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